SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 270 filers reported holding SAGE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,761,600 | -63.4% | 80,000 | -67.3% | 0.47% | -77.5% |
| Q1 2023 | $10,280,200 | -25.1% | 245,000 | -31.9% | 2.07% | -28.1% |
| Q4 2022 | $13,730,400 | -1.8% | 360,000 | +0.8% | 2.88% | +6.1% |
| Q3 2022 | $13,980,000 | +5.0% | 357,000 | -13.4% | 2.72% | -0.8% |
| Q2 2022 | $13,316,000 | +29.4% | 412,257 | +32.6% | 2.74% | +2.2% |
| Q1 2022 | $10,294,000 | -40.8% | 311,000 | -24.0% | 2.68% | -44.4% |
| Q4 2021 | $17,399,000 | +23.1% | 409,000 | +28.2% | 4.82% | +18.5% |
| Q3 2021 | $14,135,000 | +11.1% | 319,000 | +42.4% | 4.06% | +16.0% |
| Q2 2021 | $12,725,000 | +18.1% | 224,000 | +55.6% | 3.50% | +13.7% |
| Q1 2021 | $10,778,000 | -36.1% | 144,000 | -26.2% | 3.08% | -38.6% |
| Q4 2020 | $16,869,000 | +20.0% | 195,000 | -15.2% | 5.02% | +16.7% |
| Q3 2020 | $14,058,000 | +73.4% | 230,000 | +17.9% | 4.30% | +77.1% |
| Q2 2020 | $8,108,000 | +66.1% | 195,000 | +14.7% | 2.43% | +12.9% |
| Q1 2020 | $4,882,000 | -43.6% | 170,000 | +41.7% | 2.15% | -36.3% |
| Q4 2019 | $8,663,000 | – | 120,000 | – | 3.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |